双示踪剂PET/CT定量生物标志物预测mCRPC患者PSMA-RLT疗效
模型在训练队列(n=24)准确率95.8%,外部验证队列(n=13)84.6%,一致病灶SUVmean是最强预测特征,SUVmean≥12.1 g/mL者更可能响应。
要点
- 一致病灶(PSMA+/FDG+)的SUVmean是预测PSMA-RLT响应的最强特征。
- SUVmean≥12.1 g/mL的患者更可能从PSMA-RLT中获益。
- 骨转移灶高SUVmax被识别为负向预后标志。
核心结论
- 双示踪剂PET/CT定量指标,尤其是一致病灶特征,有望预测mCRPC患者对PSMA-RLT的响应。
- 研究提示可超越二元入选标准,转向生物标志物驱动的患者选择。
研究设计与样本
- 治疗前均行[68Ga]Ga-PSMA-11与[18F]F-FDG PET/CT,自动化流程分割病灶、融合图像并提取一致与非一致病灶的定量特征。
- 决策树模型在维也纳队列(n=24)训练,在奥格斯堡独立队列(n=13)验证,并用SHAP分析识别关键预测特征。
主要发现
- 决策树模型训练队列准确率95.8%,外部验证队列准确率84.6%。
- 一致病灶的SUVmean是最具预测价值的特征。
- 一致病灶SUVmean≥12.1 g/mL的患者更可能响应治疗。
- 骨转移灶高SUVmax为负向预后标志。
关键数值与推荐
- 一致病灶定义为PSMA阳性且FDG阳性(PSMA+/FDG+)。
- 预测响应的一致病灶SUVmean阈值为≥12.1 g/mL。
临床怎么用
- 对拟行PSMA-RLT的mCRPC患者,可考虑双示踪剂PET/CT定量评估一致病灶SUVmean以辅助筛选。
- 骨转移灶高SUVmax提示预后较差,可能需更密切监测或联合策略。
局限性
- 回顾性双中心设计,需更大规模前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) has emerged as a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). However, current patient selection methods – largely based on qualitative imaging criteria – may impede precision and efficacy of treatment. We aimed to evaluate the predictive value of quantitative imaging biomarkers derived from dual-tracer [68 Ga]Ga-PSMA-11 and [18F]F-FDG PET/CT, with a focus on concordant lesions. METHODS: Thirty-seven mCRPC patients from two institutions underwent [68 Ga]Ga-PSMA-11 and [18F]F-FDG PET/CT prior to receiving at least two cycles of [177Lu]Lu-PSMA therapy. An automated pipeline enabled lesion segmentation, dual-tracer image fusion, and extraction of quantitative features from concordant (PSMA + /FDG +) and non-concordant lesions. A decision tree model was developed on the Vienna cohort (n = 24) and validated on an independent cohort from Augsburg (n = 13). SHAP analysis was used to identify key predictive features. RESULTS: The decision tree achieved 95.8% accuracy in the training cohort and 84.6% in external validation. SUVmean of concordant lesions was the most predictive features. Patients with SUVmean[PSMA Concordant] ≥ 12.1 g/mL were more likely to respond. Organ-specific analysis further identified high SUVmax in bone metastases as a negative prognostic marker. CONCLUSIONS: Quantitative metrics from dual-tracer PET, particularly those characterizing concordant lesions, show promise for predicting response to PSMA-RLT. These preliminary findings highlight the potential to move beyond binary eligibility criteria toward a more nuanced, biomarker-driven approach to patient selection.
引用
- Xue S, Einspieler H, Wen S, et al. Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center study. Eur J Nucl Med Mol Imaging. 2026. PMID: 41489652. doi:10.1007/s00259-025-07700-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。